Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."


TSX:TST - Post by User

Bullboard Posts
Comment by CorporateStoogeon Dec 22, 2012 2:08pm
183 Views
Post# 20765580

RE: Options

RE: Options

This is pretty simple.  Endo didn't care to or want to deal with another 3 yrs of bloodletting for a product that essentially competes head to head with another product of theirs that is already approved.

Trials are pricey, Endo has already coughed up a fair bit and would need to cough up more to get it approved in it's home country.  I have no doubt that in a little spreadsheet somewhere, there's a cell that has ROI in it and once the FDA didn't care to play ball on getting Urocidin out in fast order, the ROI cell turned into a number that goes beyond the 'normal practices of Endo'.  All big companies have such a protocol, Endo is no different.  Now they free up some short term funds to create the next uncrushable version of another high margin pill that's already out there.....

Most interesting however is the Endo Analyst Day number that we all thought light.  Well, if $100M per annum is the royalty rate then we'll do nicely.  Remember, up to that point, Endo disavowed any knowledge of our little hobby and they really didn't have to make a hullabaloo that day either....but they did....and they of course knew already that the trial was going to fold....so the rev numbers presented were worst case....not a bad worst case......

Make no mistake, this ain't the news anyone with aspirations for this stock was expecting....but it's not terminal......far from it

The two biggest questions now are:

1) Where will you get money from? ( I expect the interim financials NR means something to some people here...I know it means something to me......hmmmmm)

2) When (not if) will you make the submission to HC? (And the 10th better not be McRae telling us of their plans to meet with HC reps some time soon to establish a meeting frequency to decide on when to meet next......hear that Graeme!)

All other questions are irrelevant at this point....Urocidin still is effective, statistics don't lie...this is just a company (Endo) deciding to go a different direction....

BTW, Immunocidin will ramp shortly, as will Sin Susto....as will Oncocidin.....peace friends, this Christmas ain't as merry as I wanted it to be....but we're still in good shape.....(for a while at least).

Bullboard Posts